Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
new york
8
×
new york blog main
new york top stories
clinical trials
boston top stories
national top stories
amgen
inclisiran
regeneron pharmaceuticals
sanofi
alnylam pharmaceuticals
biotech
fda
pcsk9 inhibitors
san francisco blog main
alirocumab
cancer
cholesterol
drugs
evolocumab
pcsk9
praluent
repatha
rna interference
san francisco top stories
startups
the medicines co.
agios pharmaceuticals
akcea therapeutics
akili interactive labs
anylam pharmaceuticals
bruce leuchter
cancer drugs
cardiomyopathy
click therapeutics
clickotine
community oncology alliance
What
medicines
8
×
drug
cholesterol
medco
fda
lowering
new
alnylam
announced
helped
medicine
sets
twice
year
aces
acquire
ago
agreed
aim
akcea
amyloidosis
approved
attr
available
backs
based
battle
bets
big
billion
boost
bringing
brings
cancer
cash
ceo
change
clears
click
closer
Language
unset
Current search:
" new york "
×
medicines
×
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum